Moderna Poised to Take Vaccine Spotlight With Data Due
Initial verdict could come in days as national cases ramp up
Effectiveness expected to be similar to Pfizer’s 90% rate
WATCH: Moderna Inc. says it has accumulated enough volunteers to allow a preliminary analysis of its Covid-19 vaccine shot. Daybreak: Asia.” (Source: Bloomberg)
Now it’s Moderna Inc.’s time to be in the spotlight.
The same U.S. explosion of Covid-19 cases that helped Pfizer Inc. get results for its vaccine trial earlier this week is helping speed along Moderna’s trial. Moderna said Wednesday its study has accumulated more than 53 infections, allowing a preliminary analysis of the shot’s effectiveness to begin. The shares jumped.
